BMBeth A. Mueller

Beth A. Mueller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Beth A. Mueller has a total of 173 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Childhood Cancer and Leukemia International Consortium (CLIC): Expanding global collaboration in pediatric cancer etiology research

    by Ana M. Mora, Juan Manuel Mejía-Arangure, John D. Dockerty, Wafaa M. Rashed, Juan Carlos Núñez-Enríquez, Anssi Auvinen, Helen Bailey, Audrey Bonaventure, Pei-Chen Lee, Eric J. Chow, et al.

  • Nonchromosomal birth defects and risk of childhood acute leukemia: An assessment in 15 000 leukemia cases and 46 000 controls from the Childhood Cancer and Leukemia International Consortium

    by Philip J. Lupo, Tiffany M. Chambers, Beth A. Mueller, Jacqueline Clavel, John D. Dockerty, David R. Doody, Friederike Erdmann, Sameera Ezzat, Tommaso Filippini, Johnni Hansen, et al.

    Although recent studies have demonstrated associations between nonchromosomal birth defects and several pediatric cancers, less is known about their role on childhood leukemia susceptibility. Using data from the Childhood Cancer and Leukemia International Consortium, we evaluated associations between nonchromosomal birth defects and childhood leukemia. Pooling consortium data from 18 questionnaire‐based and three registry‐based case‐control studies across 13 countries, we used multivariable logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between a spectrum of birth defects and leukemia. Our analyses included acute lymphoblastic leukemia (ALL, n = 13 115) and acute myeloid leukemia (AML, n = 2120) cases, along with 46 172 controls. We used the false discovery rate to account for multiple comparisons. In the questionnaire‐based studies, the prevalence of birth defects was 5% among cases vs 4% in controls, whereas, in the registry‐based studies, the prevalence was 11% among cases vs 7% in controls. In pooled adjusted analyses, there were several notable associations, including (1) digestive system defects and ALL (OR = 2.70, 95% CI: 1.46‐4.98); (2) congenital anomalies of the heart and circulatory system and AML (OR = 2.86, 95% CI: 1.81‐4.52) and (3) nervous system defects and AML (OR = 4.23, 95% CI: 1.50‐11.89). Effect sizes were generally larger in registry‐based studies. Overall, our results could point to novel genetic and environmental factors associated with birth defects that could also increase leukemia susceptibility. Additionally, differences between questionnaire‐ and registry‐based studies point to the importance of complementary sources of birth defect phenotype data when exploring these associations.


  • Population-Based Impact of Rurality and Neighborhood-Level Socioeconomic Disadvantage on Pediatric Cancer Mortality in Washington State

    by Timothy J.D. Ohlsen, David R. Doody, Beth A. Mueller, Arti D. Desai, Eric J. Chow

    Background: Childhood cancer–related mortality differs by socioeconomic factors, but the impact of residential location, including rurality and neighborhood-level socioeconomic disadvantage, is not well-characterized. Methods: This retrospective cohort study linked Washington State cancer registry data (1992–2013) to state birth (1974–2013) and death records (1992–2013) to identify residents <20 years diagnosed with cancer (n = 4,306). Census-based rural–urban commuting area codes and Area Deprivation Index (ADI) defined rural residence and neighborhood socioeconomic disadvantage at time of cancer diagnosis, respectively. Neighborhoods in the highest state ADI quintile were classified as the most disadvantaged. Kaplan–Meier estimates and Cox hazards models, adjusted for key characteristics, were used to compare mortality by rural and ADI classification. Results: Five-year overall survival for children from non-rural low ADI neighborhoods (referent) was 80.9%±0.8%, versus 66.4%±2.9% from non-rural high ADI neighborhoods, 69.4%±3.8% from rural low ADI neighborhoods, and 66.9%±3.8% from rural high ADI neighborhoods (P < 0.01 for each comparison versus referent). Compared with the referent group, children from comparator neighborhoods had a greater mortality risk: Rural low ADI [hazard ratio (HR), 1.50; 95% confidence interval (CI), 1.12–2.02], rural high ADI (HR, 1.53; 95% CI, 1.16–2.01), and non-rural high ADI (HR, 1.64; 95% CI, 1.32–2.04). Associations of ADI and rurality with mortality varied in sub-analyses by cancer type. Conclusions: Children with cancer living in rural and/or socioeconomically disadvantaged neighborhoods at diagnosis experienced greater mortality relative to those without either factor. Impact: Future investigation is needed to examine how rurality and poverty potentially impact healthcare utilization and health-related outcomes in pediatric oncology.


  • Infant feeding practices and childhood acute leukemia: Findings from the Childhood Cancer & Leukemia International Consortium

    by Jeremy M. Schraw, Helen D. Bailey, Audrey Bonaventure, Ana M. Mora, Eve Roman, Beth A. Mueller, Jacqueline Clavel, Eleni T. Petridou, Maria Karalexi, Evangelia Ntzani, et al.

    Increasing evidence suggests that breastfeeding may protect from childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). However, most studies have limited their analyses to any breastfeeding, and only a few data have examined exclusive breastfeeding, or other exposures such as formula milk. We performed pooled analyses and individual participant data metaanalyses of data from 16 studies (N = 17 189 controls; N = 10 782 ALL and N = 1690 AML cases) from the Childhood Leukemia International Consortium (CLIC) to characterize the associations of breastfeeding duration with ALL and AML, as well as exclusive breastfeeding duration and age at introduction to formula with ALL. In unconditional multivariable logistic regression analyses of pooled data, we observed decreased odds of ALL among children breastfed 4 to 6 months (0.88, 95% CI 0.81‐0.96) or 7 to 12 months (OR 0.85, 0.79‐0.92). We observed a similar inverse association between breastfeeding ≥4 months and AML (0.82, 95% CI 0.71‐0.95). Odds of ALL were reduced among children exclusively breastfed 4 to 6 months (OR 0.73, 95% CI 0.63‐0.85) or 7 to 12 months (OR 0.70, 95% CI 0.53‐0.92). Random effects metaanalyses produced similar estimates, and findings were unchanged in sensitivity analyses adjusted for race/ethnicity or mode of delivery, restricted to children diagnosed ≥1 year of age or diagnosed with B‐ALL. Our pooled analyses indicate that longer breastfeeding is associated with decreased odds of ALL and AML. Few risk factors for ALL and AML have been described, therefore our findings highlight the need to promote breastfeeding for leukemia prevention.


  • Open Access

    Birthweight and all-cause mortality after childhood and adolescent leukemia: a cohort of children with leukemia from Denmark, Norway, Sweden, and Washington State

    by Anne Gulbech Ording, Lotte Brix Christensen, Tone Bjørge, David R. Doody, Anders Ekbom, Ingrid Glimelius, Tom Grotmol, Gunnar Larfors, Beth A. Mueller, Karin E. Smedby, et al.

    Background: High birthweight may predispose children to acute lymphoid leukemia, whereas low birthweight is associated with childhood morbidity and mortality. Low and high birthweight have been inconsistently associated with mortality in children with leukemia. Material and methods: In a cohort of childhood and adolescent leukemia (0–19 years) patients from registries in Denmark, Norway, Sweden, and Washington State in the United States (1967–2015), five-year all-cause mortality was assessed by birthweight and other measures of fetal growth using the cumulative incidence function and Cox regression with adjustment for sex, diagnosis year, country, the presence of Down’s syndrome or other malformations, and type of leukemia. Results: Among 7148 children and adolescents with leukemia (55% male), 4.6% were low (1–2 years old; 1.0 (95% CI: 0.6, 1.5) for 3–8 years old; 1.0 (95% CI: 0.6, 1.8) for 9–13 years old; and 1.2 (95% CI: 0.7, 2.1) for 14–19 years old, and were similar for size for gestational age and Ponderal index. In analyses restricted to children born full term (37–41 weeks of gestation), results were only slightly attenuated but risk was markedly increased for infants aged ≤1 year (HR for low birthweight = 3.2, 95% CI: 1.2, 8.8). Conclusion: This cohort study does not suggest that low birthweight or SGA is associated with increased five-year all-cause mortality risk among children with any type of childhood leukemia or acute lymphoblastic leukemia, specifically, beyond infancy.


  • Antidepressant continuation in pregnancy and risk of gestational diabetes

    by Paige D. Wartko, Noel S. Weiss, Daniel A. Enquobahrie, K.C. Gary Chan, Alyssa Stephenson‐Famy, Beth A. Mueller, Sascha Dublin

    Purpose: Previous studies observed modestly higher risk of gestational diabetes (GDM) associated with antidepressant use in pregnancy, potentially due to confounding by indication. We assessed the association of antidepressant continuation in pregnancy with GDM, as well as blood glucose levels, after accounting for confounding.Methods: We conducted a retrospective cohort study of singleton live births from 2001 to 2014 to women enrolled in Kaiser Permanente Washington, an integrated health care delivery system, utilizing electronic health data and linked Washington State birth records. We required that women have ≥1 antidepressant prescription fills ≤6 months before pregnancy. Women with an antidepressant fill during pregnancy were categorized as “continuers” (n = 1634); those without a fill were “discontinuers” (n = 1211). We calculated relative risks (RRs) for GDM and mean differences in screening blood glucose levels using generalized estimating equations with inverse probability of treatment weighting to account for baseline characteristics, including mental health conditions and indicators of mental health severity.Results: Compared with discontinuers, antidepressant continuers had comparable risk of GDM (RR: 1.10; 95% confidence interval [CI], 0.84‐1.44) and blood glucose levels (mean difference: 2.3 mg/dL; 95% CI, −1.5 to 6.1 mg/dL). We observed generally similar results for specific antidepressants, with the potential exceptions of risk of GDM associated with sertraline (RR: 1.30; 95% CI, 0.90‐1.88) and venlafaxine (RR: 1.52; 95% CI, 0.87‐2.68), but neither association was statistically significant.Conclusions: Our study suggests that overall, women who continue antidepressants in pregnancy are not at increased risk for GDM or higher blood glucose, although further study may be warranted for sertraline and venlafaxine.


  • Pregnancy course, infant outcomes, rehospitalization, and mortality among women with intellectual disability

    by Beth A. Mueller, Deborah Crane, David R. Doody, Sally N. Stuart, Melissa A. Schiff


  • Obstetrical and infant outcomes among women with neoplasms during pregnancy

    by Xin Niu, Christopher I. Li, Beth A. Mueller

    One in 1,000 pregnancies is complicated by malignancies. Prevalence is greater for benign neoplasms. Adverse outcomes among women with malignancies have been reported. Less is known of postpartum outcomes for infants, or outcomes among women with benign neoplasms.


  • Pregnancy Outcomes in Women with Spinal Cord Injuries: A Population‐Based Study

    by Deborah A. Crane, David R. Doody, Melissa A. Schiff, Beth A. Mueller

    Background: Pregnant women with congenital or acquired spinal cord injury face challenges due to compromised neurologic function and mobility, factors that may also affect fetal/infant health. Few studies have examined pregnancy course and longer‐term outcomes in this population.Objective: To assess pregnancy outcomes among women with spinal cord injury, paralysis, or spina bifida using population‐based data.Design: Retrospective cohort study.Setting: Washington state linked birth‐hospital discharge records.Participants: All women (N = 529) with spinal cord injury, paralysis, or spina bifida with singleton live birth deliveries 1987‐2012, and a comparison group of women without disabilities (N = 5282).Methods: Diagnosis codes were screened to identify cases and a 10:1 random sample of comparison women. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated overall and separately for each condition using multivariable regression. Subsequent hospitalizations or death were identified via linkage to hospital discharge/death records for 2 years after delivery.Main Outcome Measurements: Pregnancy course (weight gain, gestational diabetes, preeclampsia, infection, venous thromboembolism), delivery/labor characteristics, infant characteristics (birthweight/size, gestational age), and longer‐term outcomes (occurrence/reasons for maternal/infant rehospitalization, mortality).Results: Women with these spinal conditions had increased adjusted risks of prenatal urinary tract infection/pyelonephritis (RR 26.43, 95% CI 13.97‐49.99), venous thromboembolism (RR 9.16, 95% CI 2.17‐38.60), preterm rupture of membranes (RR 2.15, 95% CI 1.18‐3.90), and cesarean delivery (RR 1.88, 95% CI 1.70‐2.09). They had longer hospitalizations and increased rehospitalization (RR 1.54, 95% CI 1.28‐1.87), including for postpartum depression (RR 8.15, 4.29‐15.48) or injury (RR 13.05, 95% CI 6.60‐25.81). Their infants were more often small for gestational age (RR 1.65, 95% CI 1.33‐2.06), but had no increased risk of rehospitalization or death.Conclusions: We observed no increased long‐term morbidity among infants of women with these conditions. Possible increased maternal morbidities during the first postpartum years indicate areas for intervention.Level of Evidence: III.


  • Hospitalization and mortality among pediatric cancer survivors: a population-based study

    by Beth A. Mueller, David R. Doody, Noel S. Weiss, Eric J. Chow

    We examined serious long-term outcomes among childhood cancer survivors using population-based data.